Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
For decades, a fundamental strategy for treating advanced prostate cancer has been to block testosterone, a male-associated hormone (or androgen) that drives the growth and spread of the malignancy. This form of treatment, which is called androgen deprivation therapy (ADT), slows the cancer’s progression, but also causes side effects including weight gain, decreased muscle mass and fatigue. Now, concern is mounting about another complication of ADT: the increased risk of cardiovascular disease.